Literature DB >> 29251697

Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.

Felice Gragnano1, Francesco Natale, Claudia Concilio, Fabio Fimiani, Arturo Cesaro, Simona Sperlongano, Mario Crisci, Giuseppe Limongelli, Raffaele Calabrò, Mariagiovanna Russo, Enrica Golia, Paolo Calabrò.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29251697     DOI: 10.2459/JCM.0000000000000611

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


× No keyword cloud information.
  11 in total

Review 1.  Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region.

Authors:  Zhen-Vin Lee; Elmer Jasper Llanes; Renan Sukmawan; Nuntakorn Thongtang; Huynh Quang Tri Ho; Philip Barter
Journal:  Lipids Health Dis       Date:  2021-04-15       Impact factor: 3.876

2.  Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania.

Authors:  Cristiana-Elena Vlad; Liliana Foia; Laura Florea; Irina-Iuliana Costache; Andreea Covic; Roxana Popescu; Delia Reurean-Pintilei; Adrian Covic
Journal:  Lipids Health Dis       Date:  2021-01-11       Impact factor: 3.876

3.  PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study.

Authors:  Mingtong Xu; Xiaoxue Zhu; Junyan Wu; Yuling Zhang; Dong Zhao; Xuhong Wang; Yanhua Ding; Yu Cao; Chengqian Li; Wei Hu; Jianlong Sheng; Zhu Luo; Zeqi Zheng; Jinfang Hu; Jianying Liu; Xiaoyang Zhou; Aizong Shen; Xiaomei Ding; Yongdong Zhang; Yonggang Zhao; Yijing Li; Sheng Zhong; Shimin An; Jianjun Zou; Li Yan
Journal:  BMC Med       Date:  2022-01-18       Impact factor: 8.775

4.  Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.

Authors:  Chang-Sheng Sheng; Ya Miao; Lili Ding; Yi Cheng; Dan Wang; Yulin Yang; Jingyan Tian
Journal:  Lipids Health Dis       Date:  2022-02-10       Impact factor: 3.876

5.  Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.

Authors:  Fei Gao; Zhi Jian Wang; Xiao Teng Ma; Hua Shen; Li Xia Yang; Yu Jie Zhou
Journal:  Lipids Health Dis       Date:  2021-09-12       Impact factor: 3.876

6.  Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial.

Authors:  Anete Kaldal; Serena Tonstad; Jarle Jortveit
Journal:  BMC Cardiovasc Disord       Date:  2021-12-16       Impact factor: 2.298

7.  Factors associated with dyslipidemia and its prevalence among Awash wine factory employees, Addis Ababa, Ethiopia: a cross-sectional study.

Authors:  Daniel Angassa; Samrawit Solomon; Awol Seid
Journal:  BMC Cardiovasc Disord       Date:  2022-01-30       Impact factor: 2.298

8.  The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy.

Authors:  Valentina Maria Caso; Simona Sperlongano; Biagio Liccardo; Emanuele Romeo; Sergio Padula; Fortunato Arenga; Antonello D'Andrea; Pio Caso; Paolo Golino; Gerardo Nigro; Vincenzo Russo
Journal:  J Clin Med       Date:  2022-01-18       Impact factor: 4.241

9.  An impact of lipid profile and lipid lowering drugs on ≥70 year olds of an upper socioeconomic class: a retrospective cohort study.

Authors:  Yehudit Eden Friedman; David M Steinberg; Michal Canetti; Ido Cohen; Shlomo Segev; Ophira Salomon
Journal:  Lipids Health Dis       Date:  2021-09-29       Impact factor: 3.876

10.  Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  BMC Cardiovasc Disord       Date:  2021-08-09       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.